Reduced GATA6 activity may directly impact metastatic progression of lung adenocarcinoma [41], while overexpression of GATA6 is associated with poor prognosis in esophageal adenocarcinoma [42]. This evidence concerns the gene GATA6 and esophageal adenocarcinoma.